Eicosapentaenoic Acid and Oxypurinol in the Treatment of Muscle Wasting in a Mouse Model of Cancer Cachexia

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Vaughan, Vanessa C ^a   Sullivan Gunn, Melanie ^b   Hinch, Edward ^a   Martin, Peter ^a   Lewandowski, Paul A ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b VICTORIA UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTIOXIDANT; ATROGIN 1; CATALASE; DNA; GLUTATHIONE PEROXIDASE 1; ICOSAPENTAENOIC ACID; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; MUSCLE RING FINGER 1 PROTEIN; OXIPURINOL; PROTEIN UBB; UBIQUITIN; UNCLASSIFIED DRUG; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

ANIMAL CELL; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CACHEXIA; CONTROLLED STUDY; DISEASE MODEL; DNA DAMAGE; ENZYME ACTIVITY; FEMALE; GASTROCNEMIUS MUSCLE; MOUSE; MUSCLE ATROPHY; NONHUMAN; PROTEIN DEGRADATION; RNA ANALYSIS; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; CACHEXIA; CATALASE; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; MICE; MICE, INBRED BALB C; MICE, NUDE; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGAN SIZE; OXIDATIVE STRESS; OXYPURINOL; SUPEROXIDE DISMUTASE; TUMOR BURDEN; WEIGHT LOSS; XANTHINE OXIDASE;

MUS;

EID: 84866654236     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045900     Document Type: Article

References (36)

1. Tijerina AJ, (2004) The biochemical basis of metabolism in cancer cachexia. Dimens Crit Care Nurs 23: 237-243.
2. Teunissen SCCM, Wesker W, Kruitwagen C, de Haes HCJM, Voest EE, et al. (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 34: 94-104 doi:10.1016/j.jpainsymman.2006.10.015.
3. Skipworth RJE, Stewart GD, Dejong CHC, Preston T, Fearon KCH, (2007) Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 26: 667-676 doi:10.1016/j.clnu.2007.03.011.
4. Argilés JM, (2005) Cancer-associated malnutrition. Eur J Oncol Nurs 9Suppl 2: S39-50 doi:10.1016/j.ejon.2005.09.006.
5. Russell ST, Eley H, Tisdale MJ, (2007) Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II. Cell Signal 19: 1797-1806 doi:10.1016/j.cellsig.2007.04.003.
6. Sullivan-Gunn MJ, Campbell-O'Sullivan SP, Tisdale MJ, Lewandowski PA, (2011) Decreased NADPH oxidase expression and antioxidant activity in cachectic skeletal muscle. J Cachexia Sarcopenia Muscle 2: 181-188 doi:10.1007/s13539-011-0037-3.
7. Barreiro E, la Puente de B, Busquets S, López-Soriano FJ, Gea J, et al. (2005) Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. Febs Lett 579: 1646-1652 doi:10.1016/j.febslet.2005.02.017.
8. Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, et al. (2003) Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 81: 664-673 doi:10.1007/s00109-003-0476-1.
9. Meneshian A, Bulkley GB, (2002) The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation 9: 161-175 doi:10.1038/sj.mn.7800136.
10. Pacher P, Nivorozhkin A, Szabó C, (2006) Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58: 87-114 doi:10.1124/pr.58.1.6.
11. Kaynar H, Meral M, Turhan H, Keles M, Celik G, et al. (2005) Glutathione peroxidase, glutathione-S-transferase, catalase, xanthine oxidase, Cu-Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and non-small cell lung cancer. Cancer Lett 227: 133-139 doi:10.1016/j.canlet.2004.12.005.
12. Springer J, Hartmann A, Palus S, Adams V, Harsdorf von R, et al. (2009) The Xanthine Oxidase Inhibitors Oxypurinol and Allopurinol Reduce Wasting and Improve Cardiac Function in Experimental Cancer Cachexia. J Card Fail 15: S22-S22.
13. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, et al. (2007) Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 46: 623-644.
14. Deby C, Deby-Dupont G, Noël FX, Lavergne L, (1981) In vitro and in vivo arachidonic acid conversions into biologically active derivatives are enhanced by uric acid. Biochem Pharmacol 30: 2243-2249.
15. Khal J, Wyke SM, Russell ST, Hine AV, Tisdale MJ, (2005) Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br J Cancer 93: 774-780 doi:10.1038/sj.bjc.6602780.
16. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, et al. (2003) Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 237: 384-389 doi:10.1097/01.SLA.0000055225.96357.71.
17. Glickman MH, Ciechanover A, (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiological Reviews 82: 373-428 doi:10.1152/physrev.00027.2001.
18. Palma L de, Marinelli M, Pavan M, Orazi A, (2007) Ubiquitin ligases MuRF1 and MAFbx in human skeletal muscle atrophy. Joint Bone Spine 75: 53-57 doi:10.1016/j.jbspin.2007.04.019.
19. Li M, Zhu Q, Hu C, Giesy JP, Kong Z, et al. (2011) Protective effects of eicosapentaenoic acid on genotoxicity and oxidative stress of cyclophosphamide in mice. Environ Toxicol 26: 217-223 doi:10.1002/tox.20546.
20. Hardman WE, (2004) (n-3) fatty acids and cancer therapy. J Nutr 134: 3427S-3430S.
21. Barber MD, (2001) Cancer cachexia and its treatment with fish-oil-enriched nutritional supplementation. Nutrition 17: 751-755.
22. Fearon KCH, Barber MD, Moses AWG, Ahmedzai SH, Taylor GS, et al. (2006) Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24: 3401-3407 doi:10.1200/JCO.2005.04.5724.
23. Donohoe CL, Ryan AM, Reynolds JV, (2011) Cancer Cachexia: Mechanisms and Clinical Implications. Gastroenterol Res Pract 2011: 1-13 doi:10.1155/2011/601434.
24. Wyke SM, Tisdale MJ, (2005) NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer 92: 711-721 doi:10.1038/sj.bjc.6602402.
25. Russell ST, Tisdale MJ, (2005) Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia. Prostaglandins Leukot Essent Fatty Acids 72: 409-414 doi:10.1016/j.plefa.2005.03.002.
26. van Norren K, Kegler D, Argilés JM, Luiking Y, Gorselink M, et al. (2009) Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br J Cancer 100: 713-722 doi:10.1038/sj.bjc.6604905.
27. Penna F, Busquets S, Pin F, Toledo M, Baccino FM, et al. (2011) Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. J Cachexia Sarcopenia Muscle 2: 95-104 doi:10.1007/s13539-011-0028-4.
28. Stehr SN, Heller AR, (2006) Omega-3 fatty acid effects on biochemical indices following cancer surgery. Clin Chim Acta 373: 1-8 doi:10.1016/j.cca.2006.04.024.
29. Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ, (2001) Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 61: 3604-3609.
30. Beck SA, Smith KL, Tisdale MJ, (1991) Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 51: 6089-6093.
31. Biondo PD, Brindley DN, Sawyer MB, Field CJ, (2008) The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. The Journal of Nutritional Biochemistry 19: 787-796 doi:10.1016/j.jnutbio.2008.02.003.
32. Valavandis A, Vlachogianni T, Fiotakis C, (2009) 8-hydroxy-2'-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. Journal of environmental science and health Part C 27: 120-139 doi:10.1080/10590500902885684.
33. Tate GA, Mandell BF, Karmali RA, Laposata M, Baker DG, et al. (1988) Suppression of monosodium urate crystal-induced acute inflammation by diets enriched with gamma-linolenic acid and eicosapentaenoic acid. Arthritis Rheum 31: 1543-1551.
34. Hashimoto M, Hossain S, Yamasaki H, Yazawa K, Masumura S, (1999) Effects of eicosapentaenoic acid and docosahexaenoic acid on plasma membrane fluidity of aortic endothelial cells. Lipids 34: 1297-1304.
35. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, et al. (2000) Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 285: 194-204 doi:10.1006/abio.2000.4753.
36. Sullivan-Gunn M, Hinch E, Vaughan V, Lewandowski P, (2011) Choosing a stable housekeeping gene and protein is essential in generating valid gene and protein expression results. Br J Cancer 104: 1055-1055 doi:doi:10.1038/bjc.2011.35.